Biogen's Leqembi may not be widely used for Alzheimer's in Europe - report
digicomphoto

A group of nine neurologists and researchers familiar with Alzheimer's disease say that Biogen (NASDAQ:BIIB) and Eisai's (OTCPK:ESALF) (OTCPK:ESAIY) Leqembi (lecanemab) may not see wide use in Europe over efficacy and brain swelling concerns.
In interviews with Reuters, the Alzheimer's experts also noted that treatment's high price, twice monthly infusions, and the need to monitor for brain swelling as obstacles to greater use of Leqembi.

Carlo Colosimo, chairman of the department of neurology at Italy's Santa Maria University Hospital, expressed concern Leqembi would have clinical significance for patients.
The European Medicines Agency is currently reviewing Leqembi with a decision expected later this year or in early 2024.

More on Leqembi

FDA panel recommends full approval for Biogen, Eisai Alzheimer's drug
Alzheimerâs disease market expected to reach $14B globally in 2030